Filana Therapeutics, Inc. (FLNA)
0.5456
+0.06
(+13.45%)
USD |
NASDAQ |
Nov 18, 16:00
0.5841
+0.04
(+7.06%)
After-Hours: 20:00
Filana Therapeutics Enterprise Value : -54.16M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | -54.16M |
| November 16, 2026 | -54.71M |
| November 13, 2026 | -56.96M |
| November 12, 2026 | -55.81M |
| November 11, 2026 | -54.10M |
| November 10, 2026 | -54.09M |
| November 09, 2026 | -53.59M |
| November 06, 2026 | -55.57M |
| November 05, 2026 | -55.66M |
| November 04, 2026 | -49.60M |
| November 03, 2026 | -48.48M |
| November 02, 2026 | -50.15M |
| October 30, 2026 | -47.10M |
| October 29, 2026 | -45.30M |
| October 28, 2026 | -45.66M |
| October 27, 2026 | -45.78M |
| October 26, 2026 | -47.61M |
| October 23, 2026 | -46.42M |
| October 22, 2026 | -45.49M |
| October 21, 2026 | -45.23M |
| October 20, 2026 | -43.77M |
| October 19, 2026 | -44.09M |
| October 16, 2026 | -43.02M |
| October 15, 2026 | -40.15M |
| October 14, 2026 | -41.61M |
| Date | Value |
|---|---|
| October 13, 2026 | -41.02M |
| October 12, 2026 | -39.71M |
| October 09, 2026 | -37.34M |
| October 08, 2026 | -37.50M |
| October 07, 2026 | -37.40M |
| October 06, 2026 | -34.44M |
| October 05, 2026 | -34.69M |
| October 02, 2026 | -31.63M |
| October 01, 2026 | -29.92M |
| September 30, 2026 | -33.88M |
| September 29, 2026 | -38.01M |
| September 28, 2026 | -41.46M |
| September 25, 2026 | -46.54M |
| September 24, 2026 | -45.35M |
| September 23, 2026 | -40.65M |
| September 22, 2026 | -32.92M |
| September 21, 2026 | -46.96M |
| September 18, 2026 | -47.61M |
| September 17, 2026 | -47.90M |
| September 16, 2026 | -49.63M |
| September 15, 2026 | -49.03M |
| September 14, 2026 | -47.96M |
| September 11, 2026 | -45.36M |
| September 10, 2026 | -43.60M |
| September 09, 2026 | -43.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CorMedix, Inc. | 160.77M |
| Eloxx Pharmaceuticals, Inc. | -8.293M |
| Breakthrough Chemistry, Inc. | -0.0298M |
| BioStem Technologies, Inc. | 17.64M |
| Cardiac Biotech Solutions, Inc. | 6.406M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.73M |
| Total Expenses (Quarterly) | 10.73M |
| EPS Diluted (Quarterly) | -0.2213 |
| Earnings Yield | -160.0% |
| Normalized Earnings Yield | -154.42 |